Author: Smith, Trevor R. F.; Patel, Ami; Ramos, Stephanie; Elwood, Dustin; Zhu, Xizhou; Yan, Jian; Gary, Ebony N.; Walker, Susanne N.; Schultheis, Katherine; Purwar, Mansi; Xu, Ziyang; Walters, Jewell; Bhojnagarwala, Pratik; Yang, Maria; Chokkalingam, Neethu; Pezzoli, Patrick; Parzych, Elizabeth; Reuschel, Emma L.; Doan, Arthur; Tursi, Nicholas; Vasquez, Miguel; Choi, Jihae; Tello-Ruiz, Edgar; Maricic, Igor; Bah, Mamadou A.; Wu, Yuanhan; Amante, Dinah; Park, Daniel H.; Dia, Yaya; Ali, Ali Raza; Zaidi, Faraz I.; Generotti, Alison; Kim, Kevin Y.; Herring, Timothy A.; Reeder, Sophia; Andrade, Viviane M.; Buttigieg, Karen; Zhao, Gan; Wu, Jiun-Ming; Li, Dan; Bao, Linlin; Liu, Jiangning; Deng, Wei; Qin, Chuan; Brown, Ami Shah; Khoshnejad, Makan; Wang, Nianshuang; Chu, Jacqueline; Wrapp, Daniel; McLellan, Jason S.; Muthumani, Kar; Wang, Bin; Carroll, Miles W.; Kim, J. Joseph; Boyer, Jean; Kulp, Daniel W.; Humeau, Laurent M. P. F.; Weiner, David B.; Broderick, Kate E.
Title: Immunogenicity of a DNA vaccine candidate for COVID-19 Cord-id: i1hyk962 Document date: 2020_5_20
ID: i1hyk962
Snippet: The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate ta
Document: The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19. At this time, no vaccine is available to control further dissemination of the disease. We have previously engineered a synthetic DNA vaccine targeting the MERS coronavirus Spike (S) protein, the major surface antigen of coronaviruses, which is currently in clinical study. Here we build on this prior experience to generate a synthetic DNA-based vaccine candidate targeting SARS-CoV-2 S protein. The engineered construct, INO-4800, results in robust expression of the S protein in vitro. Following immunization of mice and guinea pigs with INO-4800 we measure antigen-specific T cell responses, functional antibodies which neutralize the SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and biodistribution of SARS-CoV-2 targeting antibodies to the lungs. This preliminary dataset identifies INO-4800 as a potential COVID-19 vaccine candidate, supporting further translational study.
Search related documents:
Co phrase search for related documents- acute respiratory syndrome and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and live virus neutralization: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acute respiratory syndrome and live virus neutralization pseudovirus: 1, 2, 3, 4
- acute respiratory syndrome and live virus neutralize: 1
- acute respiratory syndrome and low respiratory disease: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory syndrome and lung antibody presence: 1
- acute respiratory syndrome and lung fluid: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lung fluid serum: 1, 2, 3
- live virus and low respiratory disease: 1
- live virus and lung fluid: 1, 2
Co phrase search for related documents, hyperlinks ordered by date